In this issue:
Timing of HCV therapy in patients awaiting transplant
Target glutaminolytic enzymes to prevent HCC in HCV?
Trends in liver transplant listings in current DAAVT era
HBsAg seropositivity protects against NAFLD?
HBx co-activates FXR, protects against HCC
Low hepatic steatosis prevalence with non-genotype 3 HCV
On-going vigilance required after SVR
. . . in patients with HCV-associated cirrhosis
Prognosis of chronic HBV in France (2008–2013)
DAAVT: safe, feasible in the elderly with chronic HCV
Please login below to download this issue (PDF)